AnaptysBio, Inc. (NASDAQ:ANAB) Receives $54.64 Average PT from Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $54.64.

Several research analysts recently issued reports on ANAB shares. Truist Financial lifted their target price on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Wedbush reiterated an “outperform” rating and issued a $42.00 target price on shares of AnaptysBio in a research note on Thursday, November 14th. HC Wainwright dropped their price target on shares of AnaptysBio from $55.00 to $52.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. UBS Group upped their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Finally, Guggenheim increased their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, October 21st.

Insider Transactions at AnaptysBio

In related news, insider Eric J. Loumeau sold 8,720 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.82, for a total transaction of $347,230.40. Following the completion of the transaction, the insider now owns 7,020 shares of the company’s stock, valued at approximately $279,536.40. The trade was a 55.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total transaction of $58,005.00. Following the completion of the sale, the insider now owns 15,398 shares in the company, valued at $595,440.66. This represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers boosted its position in shares of AnaptysBio by 1.8% during the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock valued at $745,000 after acquiring an additional 525 shares during the last quarter. Algert Global LLC boosted its holdings in shares of AnaptysBio by 11.8% in the 2nd quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after purchasing an additional 1,078 shares in the last quarter. nVerses Capital LLC increased its position in shares of AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares during the last quarter. Values First Advisors Inc. purchased a new position in shares of AnaptysBio during the 3rd quarter valued at about $49,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in AnaptysBio in the 1st quarter worth approximately $38,000.

AnaptysBio Trading Up 4.6 %

ANAB opened at $21.24 on Friday. AnaptysBio has a 1-year low of $13.36 and a 1-year high of $41.31. The company has a market cap of $646.42 million, a price-to-earnings ratio of -3.49 and a beta of -0.24. The company’s fifty day moving average price is $30.12 and its two-hundred day moving average price is $29.77.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The company had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, equities analysts forecast that AnaptysBio will post -6.02 earnings per share for the current fiscal year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.